GE Healthcare Technologies (GEHC) said Friday the NCCN clinical practice guidelines in oncology for doctors now recommend considering the use of fluoroestradiol, or FES, positron emission tomography, or PET, imaging in some individuals with lobular breast cancer.
The company said its cerianna injection is the only imaging agent approved by the US Food and Drug Administration to detect estrogen receptor positive breast cancer metastases, including lobular breast cancer.
GE Healthcare said invasive lobular cancer is the second most common type of breast cancer in the US.
Price: 70.05, Change: -1.48, Percent Change: -2.07
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。